WHAT WE ACTUALLY FOUND

What We Actually Found

Somewhere around 7,000 BCE, someone fermented something, drank too much of it, and felt terrible the next morning. Within a day or two, almost certainly, someone else sold them a cure. Guaranteed to work.

Not once in nine thousand years has it worked.

Not for lack of trying. Every civilization with alcohol had its remedy. Every era had its guarantees. The target was always the same: the symptoms. The head. The stomach. The fatigue. Remedy after remedy, generation after generation, aimed at what could be felt rather than what was actually happening.

What was actually happening -- what has always been happening -- is this: alcohol puts the body under acute oxidative stress, disrupts mitochondrial function, depletes glutathione, dysregulates GABA-A receptor function, and drives neuroinflammation. Simultaneously, at speed. The morning after drinking is not a mystery. It is measurable cellular disruption running on a compressed timeline.

Nobody built something that worked on those mechanisms. Because nobody was looking there.

We were not hangover supplement people. We came from psychedelics research, focused on addiction, working with plant compounds and their effects on the systems that govern how people feel and function. When that path closed, we looked at what the science had taught us and asked what else was possible.

What we found was dihydromyricetin.¹

What We Are Saying -- And What We Are Not

Hangovr180® is not a hangover cure. We are not claiming that. We are saying it works on the same mechanisms and metabolic pathways that alcohol disrupts -- and that it supports the proper functioning of those systems. That is it.

The formula's effects map to the structure-function claims we submitted under DSHEA:

These are structure-function claims submitted under 21 CFR 101.93. 35 submitted. Two objected to, permanently excluded. 33 remain without objection. They are the permitted, documented, mechanistic truth about what this formula does.

The charlatans were selling symptom relief. We support the mechanisms. What the body does with that support is the body's business -- not ours to claim.

What DHM Is

Dihydromyricetin -- DHM -- is a flavonoid from Hovenia dulcis, the Japanese Raisin Tree. Used in East Asian traditional medicine for centuries. Studied seriously by Western science for two decades. The published literature is extensive and continues to grow.

The breadth of the research is striking. Peer-reviewed studies demonstrate DHM activity across multiple disease-category contexts -- neurodegenerative, cardiovascular, metabolic, inflammatory, hepatic. It modulates several signaling pathways associated with aging biology in mechanistic studies. The 2023 hallmarks-of-aging benchmark publication maps mechanism categories that DHM has been shown to engage in published research.²

This is not a hangover ingredient that happens to have other uses. It is one of the most extensively studied natural compounds in the recent healthspan literature -- and its most immediately demonstrable application happens to be the context where the body's cellular systems are under the most acute, most universally recognized form of the disruption it addresses.

That is why we started here. And that is why we are not stopping here.

Why the Formula Is Three Things

DHM at 1,500mg. The research-supported dose. Most competing products use 100-300mg.

S-Acetyl Glutathione at 75mg. Alcohol specifically impairs the body's ability to synthesize glutathione -- disrupting the transsulfuration pathway at the rate-limiting enzymatic step. SAG delivers glutathione directly in gut-stable form, bypassing the synthesis problem entirely.

Fulvic Acid at 150mg at 90% purity. Improves cellular membrane permeability and meaningfully enhances DHM bioavailability. We do not fully understand the mechanism. The patent says so. We were not going to claim more than we could document.

Three ingredients because three was what more than 400 pre-commercial trials produced. Fifteen candidates evaluated. Twelve eliminated through direct observation. Three remained.

Patent pending -- US Application 18/698,010, with active PCT national phase in the United States, Canada, and Europe. 35 structure-function claims submitted under 21 CFR 101.93. Two objected to. 33 remain without objection. Patent applications use clinical terminology appropriate for USPTO filings; the consumer marketing language for Hangovr180® follows separate FDA regulations for dietary supplements under DSHEA -- which is why what you read on the label sounds different from what you read in the patent.

What Comes Next

Hangovr180® is the first brand from Next Level Brands Inc. It will not be the last.

The Tri-Power Defense formula -- DHM, SAG, Fulvic Acid -- supports the same foundational mechanisms across applications: liver health, enzyme production, mitochondrial function, antioxidant activity, metabolic support, intercellular communication. We are building toward longevity, detoxification, and metabolic health -- grounded in the same science, held to the same compliance standard.

The alcohol harm context was where we proved the formula. Because if it works on these mechanisms under the most acute, most compressed, most universally recognizable instance of cellular disruption -- nine thousand years of guaranteed cures that never once worked before it -- then the evidence for everything else it supports is excatly what you would expect.